AssetMark Inc
NKTR icon

AssetMark Inc’s Nektar Therapeutics NKTR Stock Holding History

AssetMark Inc’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$21 – 2190
2024
Q1 		$21 Buy
+1
New +$10 ﹤0.01% 1881
2019
Q2 		– Sell
-22
Closed -$11K – 1405
2019
Q1 		$11K Sell
22
-3
-12% -$1.78K ﹤0.01% 977
2018
Q4 		$12K Buy
+25
New +$15.1K ﹤0.01% 991
2018
Q1 		– Sell
-3
Closed -$3K – 1790
2017
Q4 		$3K Buy
+3
New +$1.77K ﹤0.01% 1359
2016
Q1 		– Sell
-1
Closed – – 1339
2015
Q4 		$0 Buy
+1
New +$206 ﹤0.01% 1450

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AssetMark Inc's NKTR Position: Q2 2024 in Review

AssetMark Inc sold out of Nektar Therapeutics (NKTR) in Q2 2024, closing a stake of 1 share — an estimated $21 sold.

AssetMark Inc first reported a position in NKTR in Q4 2015 and held it in 5 quarters. The position peaked at $12K in Q4 2018. 133 funds tracked by Wall St. Rank hold NKTR as of Q2 2024.

  • AssetMark Inc reported no remaining Nektar Therapeutics position as of Q2 2024 after selling out during the quarter.
  • AssetMark Inc sold 1 Nektar Therapeutics share in Q2 2024, an estimated $21.
  • AssetMark Inc first reported a position in Nektar Therapeutics in Q4 2015 and held it in 5 quarters.
  • AssetMark Inc's Nektar Therapeutics position peaked at $12K in Q4 2018.
  • 133 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2024.

Based on AssetMark Inc's 13F filing for Q2 2024, filed 13 Aug 2024.